ArticleGynecologic oncology reports2017
Ovarian cancer and the immune system.
Article in Gynecologic oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Interleukin 1 family dysregulation in serum and peritoneal fluid of ovarian cancer patients - potential clinical implications.Frontiers in oncology · 2025Article
- High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.Turkish journal of obstetrics and gynecology · 2022Article
- Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer.NPJ genomic medicine · 2022Article
- Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer.Cancers · 2021Article
- Tumor Immune Microenvironment Related Gene-Based Model to Predict Prognosis and Response to Compounds in Ovarian Cancer.Frontiers in oncology · 2021Article
- Predicting Panel of Metabolism and Immune-Related Genes for the Prognosis of Human Ovarian Cancer.Frontiers in cell and developmental biology · 2021Article
- Development and validation of an immune prognostic signature for ovarian carcinoma.Cancer reports (Hoboken, N.J.) · 2020Article
- Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.Frontiers in immunology · 2019Article
- Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short communication in response to the review of Turner et al. entitled "Ovarian cancer and the immune system - the role of targeted therapies" published in Gynecological Oncology. We believe systemic immune parameters might be a good alternative to tumor biopsy to gain insight in the immunological background of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.